On day 18 : Predose, 3*, 24 h On day 33 : Predose, 3*, 24, 120 & h
First in human dose PK and PD data
Dose levels (# of patients) 100 (1), 200 (1), 400 (4), 600 (3), 750 (26), 900 (3), 1000 (2) mg 3 hours infusion on day1, day2 and day3 (loading doses) and then weekly afterward (maintenance doses starting day8). PK Sampling Day 1: 3 hours (end infusion) post dose Day 3: predose, 3 (end of infusion), 3.25, 3.5, 4, 6, 7 to 8, and 27 to 60 hours post dose) Day8: predose Day 15: predose, 3 (end of infusion), 9 and 24 hours post Day22: predose Tumor biopsy sampling Within 14 days prior to dosing 48-to-96-hours time window (study days 5-7) following end of dose on day 3 *end of infusion samples; +PK and PD (in vitro target inhibition); **6 animals per time point; #tumor growth delay data; & tissue sampled for pharmacokinetic analysis. •A 50 mg/kg loading dose followed by 25 mg/kg every other day for 12 doses led to efficacy with significant tumor growth delay.
•The same loading dose of 50 mg/kg lead to •A) significant inhibition, 60 to 70 %, of survivin protein expression within 24 to 48 hours post dose.
•B) maximum LY2181308 concentration of 13 and 19 µg/g, in muscle and lung (low uptake tissue for ASOs) respectively.
•Hence, average LY2181308 tumor concentration of~10 to 20 µg/g should be expected to lead pharmacologically relevant target inhibition (~60%) for anti-tumor activity.
•LY2181308 peak tissue concentration and maximum target inhibition occured at approximately the same time (~24 h post administration). Hence survivin mRNA and survivin protein must have rapid half-lives or turn-over rate. •KinP and KoutP: rate constant of synthesis and degradation of survivin protein assumed to be equal in the absence of LY2181308
Results preclinical mice PK/PD
•In the presence of treatment by LY2181308, KinM is decreased and KinP is decreased.
•E1 and E2 effect of the treatment sigmoidal Emax relationships.
•Low uptake tissues included, muscle, lung, jejunum, lymphatic nodes, prostate, pancreas, spleen and skin -with LY2181308 concentrations ranging from 10 to 70 µg/g.
• High uptake tissues included the liver and kidney medulla -with LY2181308 concentrations ranging from 100 to 400 µg/µg (concentration in the kidney cortex was even higher (700 to 800 µg/g) Prediction to human Allometric scaling with a coefficient of 1 was used to predict the human PK parameter based on the monkey PK model (see table 4 and 5). •The preclinical PK model accurately predicted human plasma exposure and tumor concentrations. The terminal half-life which accounts for only <10% of the overall plasma AUC was less reliably estimated.
Results: Preclinical Monkey PK model

Results clinical PK/PD model
•Overall, the difference between the predicted and observed PK parameter values remained reasonable (median 20% (range 1.4 to 55 %)).
•The PD model predicted that LY2181308 dose > 400 mg, should lead to significant > 60% target inhibition. The observed clinical data indicated that target inhibition was indeed observed in the patient population following 750 mg dose.
•The integration of LY2181308 PK and PD preclinical data within a quantitative model did help design the first-in-human study of LY2181308 and predict with reasonable accuracy.
Discussion Conclusion
Introduction:
A modified 2'-O-methoxyethyl 18-mer second generation ASO, LY 2181308 specifically inhibits survivin mRNA, a gene coding for survivin protein.
Survivin protein, a member of the inhibitor of apoptosis protein (IAP) family, is specifically expressed in a wide range of human cancer tissues. Over-expression of survivin protein is associated with a poorer prognosis.
Hence survivin is an attractive molecular target for therapeutic intervention.
Aims:
To predict clinical efficacious dose range To select appropriate dosing regimen (dosing schedule and amount) for the first-in-human dose study of LY 2181308.
To predict LY 2181308 plasma and tissue concentration and target inhibition profiles in human.
To predict the range of LY2181308 concentration level needed for relevant efficacious target inhibition.
Material:
•Mice tissue and tumor LY 2181308 PK data, and pharmacodynamic (PD) data (i.e survivin inhibition data) and efficacy (tumor growth delay) data •Monkey plasma and tissue PK data.
•Human LY2181308 plasma and tumor biopsies and [ 11 C]LY2181308 PET concentration data and survivin target inhibition data (from tumor biopsies).
Method:
Non-linear mixed effect modeling technique (NONMEM V) was used to built
•An indirect pharmacodynamic (PD) model describing survivin mRNA and protein inhibition using preclinical target inhibition and tumor growth delay data from mouse xenografts.
• An integrated multi-compartmental plasmatissue PK model using monkey preclinical data.
Monkey PK parameter were used to predict human PK parameters (allometric scaling). Assumption that PD parameters values in human would be the same as the ones determined for mice Clinical PK/PD profiles were simulated (1000 Monte-Carlo simulations).
Results:
Average LY2181308 concentration > 10 µg/g predicted to lead to relevant target inhibition for anti-tumor activity Model predicted LY 2181308 tumor concentrations 18.8 to 54 µg/g (range) and target inhibition 50 to 90 % (5 th -95 th percentiles) following LY 2181308 750 mg in humans.
Clinical data showed LY2181308 tumor concentrations 13.9 to 52.8 µg/g (range, n=4 patients), median survivin mRNA and protein inhibition of 20 % +/-34 (SD) (n=9) and 23 % +/-63 (SD) (n=10), respectively following 750 mg.
Two patients data showed little survivin protein expression at baseline hence no reduction post treatment. When these data are excluded, the results are median survivin mRNA and protein inhibition of 34 % +/-21 (SD) (n=7) and 41 % +/-38 (SD) (n=8), respectively following 750 mg.
Multi-compartmental PK model adequately described LY 2181308 PK data. LY 2181308 has an extensive volume of distribution (> 10000 L) and low-moderate clearance (23.1 L/h) leading to a long terminal half life 32.7 days (range 22-52 days).
The model over-estimated PD effect and adequately predicted PK parameters (median difference observed -predicted PK parameters value 20 % (range 1-55).
Conclusion
Integration of LY 2181308 PK and PD preclinical data help design the first-inhuman study of LY 2181308 and predict with reasonable accuracy its outcome. Tkout P = 2 h a EC50: concentration leading to 50 % inhibition of the target; b Tkout M, survivin mRNA half life; Tkout P, survivin mRNA half life * End of infusion samples; + plasma PK and PD (tumors) sampling scheme (6 animals per time points), ** various tissues sampled for PK analysis (6 animals per time points); #tumor growth delay experiment; & tissue collected for PK assessment. 3 and 6 animals in the single and multiple dose monkey study, respectively.
